A cute rheumatic fever (RF) is a leading cause of acquired heart disease among children older than 5 years up to adolescence in developing countries. It is estimated that the prevalence of rheumatic heart disease in Indonesia is around 0.3-0.8 per 100 schoolage children aged between 5-15 years. In endemic population, approximately 0.3% suffer from RF whereas after a streptococcal infection, the incidence of RF could rise up to 3%. [1] [2] [3] Benzathine penicillin G (BPG) that had been used since the early fifties for secondary prevention of acute RF, was an important advance in controlling the disease. Stollerman et al 4 found that the serum penicillin concentration reached or even exceeded the minimal inhibitory concentration after 1 month of BPG injection. The clinical practice of monthly (4 weekly) injections of BPG has been accepted and became the method of choice for secondary prevention of rheumatic fever.
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ABSTRACT
Background The effectiveness of a single intramuscular benzathine penicillin G as a secondary prevention of acute rheumatic fever after 28 days is still controversial. The latest study showed that serum penicillin concentration was below protective level in 4 weeks after a single intramuscular injection.
Objective This study was a preliminary study to compare the inhibiting ability of benzathine penicillin G towards group A Streptococcus β-hemolyticus in 21 and 28 days after a single IM injection by using Mueller-Hinton broth method.
Methods
The inhibiting ability was measured by the serum inhibitory concentration and serum bactericidal concentration after a single intramuscular injection of benzathine penicillin G 1.2 million units.
Results
The subjects were 28 patients, with mean age of 15.5 years (SD 3.4). Keywords: Acute rheumatic fever, benzathine penicillin, serum inhibitory concentration, serum bactericidal concentration.
However, information of penicillin effectiveness in every 4-week interval still gives an interest to many scientists. Ginsburg 5 in one of his study on 6 patients, reported serum penicillin concentration at 1 month after injection was very low or even non-detectable. Another study by Lue, 6 pointed out there was a significant increase in rheumatic fever recurrences in a group given BPG every 4 weeks compared to that of the 3-week group. Meanwhile, Padmavati 7 reported the results of 3-week interval injection associated with decreased number of relapse compared to those of the 4-week group. Kaplan 8 concluded that serum penicillin concentration after 4 weeks was below 0.02 mg/ ml, a concentration considered inadequate to inhibit the streptococcus. Data comparing serum inhibitory concentration (SIC) and serum bactericidal concentration (SBC) are not available up to now. This study was a preliminary study to compare SIC and SBC in patients on day 21 and 28 after getting injection.
Methods
Serum was taken from subjects who had BPG injection (Retarpen) of 1.2 million units, in week 4 according to the schedule and then in the subsequent week 3, at our outpatient clinics of Cardiology Subdivision, Department of Child Health, Medical School, University of Indonesia/Cipto Mangunkusumo Hospital. Informed consent was taken from patients and their parents. Soon after a blood sample was taken, it was centrifuged with 5000 rpm. Serum was separated and stored in -70 o C temperature, to be sent later to the Department of Microbiology, Medical School, University of Indonesia/Cipto Mangunkusumo Hospital for SIC and SBC analysis.
All subjects, regardless of their age, received BPG (Retarpen) 1.2 million units. They were asked to come again on week 4 for blood sampling and then they received another BPG injection. Three weeks afterwards subjects were asked to come again for the second blood sample. There were 28 patients being analyzed for SIC and SBC in this study.
SIC and SBC analysis was done by MuellerHinton broth technique. 9 Serum was diluted by 1/2, 1/4, 1/8, 1/2n up to 15 tubes. In every tube, 20 ml broth was added with appropriate amount of bacteria. All tubes were incubated in 37oC for 18-24 hours.
SIC is the lowest dilution that can visibly inhibit microbacteria, while SBC is the highest dilution (lowest concentration) that able to eliminate microbacteria.
Data were presented as mean and standard deviation or median and ranges. All data were processed using Epi-info 6.0 version. P value of<0.05 was regarded as significant.
Results
There were 28 patients aged between 10 and 23 years with median age of 15.5 years. Male and female patients were equal in number. Body weight ranged from 27 to 77 kg, median weight was 46.4 kg. Subjects were rheumatic fever or rheumatic heart disease patients who came regularly to cardiology outpatient clinic for secondary prevention therapy of RF and RHD.
After analysis of SIC/SBC done by comparing serum on day 21 st and 28 th , decreased concentration was only found in 7 patients (25%), while other 21 patients (75%) maintained sufficient concentration.
SIC on day 21 st ranged from 2 to 16384 with mean concentration of 926.4 (SD 3080.1). SIC on day 28 th was 8 to 16384 with mean concentration of 1540.9 (SD 4275.1). Statistical analysis showed p value was 0.0662 ( Table 1) . The ratio between the highest and the lowest concentration was very high, so we made calculations by its logarithm. Mean SIC logarithm on day 21 st was 2.97 (SD 1.034). Mean serum inhibitory concentration logarithm on day 28 th was 3.19 (SD 0.932), p value was 0.0662 ( Table 2) . Data obtained in our study on BPG inhibiting ability against streptococcus, using SIC and SBC, did not show differences between the 3-week and the 4-week group. Inhibitory ability of SIC and SBC in most patients (21/28) of the 4-week interval group was still sufficient and concentration reduction was found in 7 out of 28 patients. These results were supported by the fact that in our experience, recurrences on the 4-week group was low and this procedure was still used as a secondary prevention in our institution. Recurrences generally developed in patients who have lack of compliance. However WHO in 196610 suggested that adults and other persons at high risk for recurrences of acute rheumatic fever should receive BPG every 3 weeks.
Based on this preliminary study we concluded that 4-week interval of 1.2 million unit BPG injection was still acceptable as secondary prophylaxis of recurrent rheumatic fever or rheumatic heart disease. Increasing the frequency to 3-week interval was not necessary due to high cost and lack of patients' compliance, especially in developing countries. Three-week prevention interval needs to be considered only in the high risk group of recurrent rheumatic fever. 
Discussion
This study was done to look at the controversy between 3 and 4-week interval of BPG (IM) injection in order to obtain maximal coverage of RF relapse. Previous studies had only used a small number of subjects and most of them were adult patients. 4, 5 Reported study on comparing SIC and SBC in both conditions was not available. Other studies focused mainly on adequate penicillin serum concentration on day 28 after BPG injection. Stollerman et al 4 stated that penicillin serum concentration reached or exceeded minimal inhibitory concentration after BPG injection at 4-week interval or more. Ginsburg 5 in his study on 26 patients reported very low or even non detectable penicillin levels 4 weeks after the administration of 1.2 million units. Another study by Lue 6 found an increased number of recurrences in 4-week injection group compared to the 3-week group. Kaplan 8 in his study using 193 serum samples concluded that penicillin concentration was below protection level after day 28. In that study, minimum penicillin serum concentration was 0.02 mg/ml.
